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Aminoglycosides, such as amikacin, are used to treat multidrug-resistant tuberculosis. However, ototoxicity is a common prob-
lem and is monitored using peak and trough amikacin concentrations based on World Health Organization recommendations.
Our objective was to identify clinical factors predictive of ototoxicity using an agnostic machine learning method. We used clas-
sification and regression tree (CART) analyses to identify clinical factors, including amikacin concentration thresholds that pre-
dicted audiometry-confirmed ototoxicity among 28 multidrug-resistant pulmonary tuberculosis patients in Botswana. Amika-
cin concentrations were measured for all patients. The quantitative relationship between predictive factors and the probability
of ototoxicity were then identified using probit analyses. The primary predictors of ototoxicity on CART analyses were cumula-
tive days of therapy, followed by cumulative area under the concentration-time curve (AUC), which improved on the primary
predictor by 87%. The area under the receiver operating curve was 0.97 on the test set. Peak and trough were not predictors in
any tree. When algorithms were forced to pick peak and trough as primary predictors, the area under the receiver operating
curve fell to 0.46. Probit analysis revealed that the probability of ototoxicity increased sharply starting after 6 months of therapy
to near maximum at 9 months. A 10% probability of ototoxicity occurred with a threshold cumulative AUC of 87,232 days · mg ·
h/liter, while that of 20% occurred at 120,000 days · mg · h/liter. Thus, cumulative amikacin AUC and duration of therapy, and
not peak and trough concentrations, should be used as the primary decision-making parameters to minimize the likelihood of
ototoxicity in multidrug-resistant tuberculosis.
Multidrug-resistant tuberculosis (MDR-TB) is a major sourceof public health concern (1–3). The mainstay for treatment
of MDR-TB has been fluoroquinolones and aminoglycosides such
as amikacin (4). However, aminoglycosides can cause both oto-
toxicity and nephrotoxicity. A potential way to decouple the tox-
icity from efficacy is to determine if the pharmacokinetic param-
eters that drive toxicity differ from those driving efficacy, as has
been the case with several other antibacterial agents (5–12).
Therefore, we measured serum amikacin concentrations in pa-
tients being treated for MDR-TB and determined aspects of phar-
macokinetic parameters that predicted toxicity.
Amikacin is an important component of MDR-TB treatment
in Botswana and is also recommended by the World Health Or-
ganization (WHO) for most countries. In 437 MDR-TB patients
in Botswana, 62% developed amikacin-associated hearing loss,
while the therapeutic success rate was 73% (13). Thus, therapeutic
success is approximately as common as ototoxicity, leading to the
commonly used and flippant statement by patients and caregivers,
“Better deaf than dead.” Currently, peak and trough concentra-
tions are used to adjust dosing to minimize chances of toxicity
under the hypothesis that toxicity is concentration dependent
(14). Here, we performed a formal literature search to assess this
relationship and found no studies that specifically addressed this
in MDR-TB. To address this possibility, we utilized classification
and regression tree analysis (CART), an algorithm of machine
learning and, hence, artificial intelligence, to identify potential
predictors of ototoxicity in MDR-TB patients and interactions
among them. CART is a nonparametric method that can examine
both linear and nonlinear interactions simultaneously, and it was
designed to handle missing data by identifying and using surro-
gate variables to minimize ascertainment bias, as is the case in data
collected for routine clinical care (9, 15–17). The classification and
ranking subroutines also yield intuitive predictors by ranking pre-
dictors in order of importance and, more importantly, calculating
threshold decision-making values above which patients would
likely have higher toxicity rates.
MATERIALS AND METHODS
Literature search. First, we searched PubMed for articles in any language
published before 1 December 2014 with search terms “amikacin,” “oto-
toxicity,” and “tuberculosis.” This was in order to systematically identify
clinical studies performed in the past on amikacin ototoxicity in MDR-TB
and the relationship to drug concentration.
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Ethics approval. The clinical study was approved by the Human Re-
search Development Committee at the Ministry of Health, Botswana, and
the University of Pennsylvania Institutional Review Board.
Study population. All MDR-TB patients 15 years of age or older who
were started on MDR-TB treatment between 1 January 2011 and 30 De-
cember 2012 and who had serum amikacin concentrations measurements
reported were included. We included all patients who had at least one
creatinine measurement within 1 month prior to or after the start of
amikacin and one follow-up creatinine measurement (within the last 6
months prior to censoring).
Patient follow-up and definitions of ototoxicity. MDR-TB patients
were treated with a standardized MDR-TB regimen composed of amika-
cin, levofloxacin, ethionamide, cycloserine, and pyrazinamide. The treat-
ment was administered daily at the observation clinic under directly ob-
served therapy. Amikacin dosage was calculated according to the WHO
recommendations and adjusted for renal function (4). Doses of 15 to 25
mg per kg of body weight (with a maximum dose of 1,000 mg per day)
were administered intramuscularly. Amikacin was administered once
daily, 7 days per week, and changed to three times per week after culture
conversion in patients who had hearing loss. The injections were discon-
tinued 4 months after culture conversion.
Hearing assessments, including subjective self-reports by patients plus
audiograms using a GSI 61 audiometer, were performed routinely as part
of clinical care provided to all patients treated for MDR-TB in Botswana.
Both self-reported hearing loss and audiometry panel tests were used to
ascertain ototoxicity, in accordance with the Botswana National Tuber-
culosis Program guidelines and American Speech-Language-Hearing As-
sociation (ASHA) criteria. Based on these criteria, audiometry-deter-
mined neurosensory hearing loss was defined as a shift or loss of 15 to 25
dB relative to the baseline averaged at two or more contiguous frequencies
in at least one ear or loss of response at 3 consecutive frequencies where
responses had previously been obtained. High-frequency audiometry was
performed on some patients who reported hearing loss; follow-up on
those patients with audiometry was performed every 3 months until 3
months after amikacin treatment. Audiometry tests were performed by
trained and experienced personnel at baseline prior to starting antituber-
culosis therapy and was repeated at least at monthly intervals during treat-
ment. Self-reported hearing was ascertained by crude functional clinical
examination and defined as the absence of usable hearing acquired during
or soon after (within 6 months) amikacin treatment. Subjective measures
of hearing loss, including tinnitus, were not included in defining ototox-
icity, and henceforth audiometry-confirmed hearing is synonymous with
ototoxicity. Clinical examinations of the vestibular functions are routinely
done during follow-up; however, the results of those tests are not pre-
sented in this study.
Pharmacokinetic sampling and modeling. We analyzed amikacin
plasma concentration levels that had been collected prospectively as part
of standard clinical monitoring in the adult MDR-TB patients. Patients
had blood drawn at 1 h and 23.5 h after an intramuscular amikacin dose.
The blood concentration measurements were made on the COBAS
INTEGRA systems, for which drug assay parameters were previously de-
scribed (18). All amikacin concentrations were comodeled in ADAPT 5
software using methods described before (9, 19, 20).
CART. Classification and regression tree (CART) analyses were per-
formed in three steps (9, 16, 21, 22). In all steps, confirmed hearing loss
was the dependent variable. First, potential predictors of ototoxicity were
examined in toto in CART models, using Salford Predictive Miner System
software (San Diego, CA). Potential predictors examined included pa-
tients’ ages, gender, initial weight, HIV infection status, receipt of antiret-
roviral therapy, and pharmacokinetic measures of drug exposures, in-
cluding amikacin dose, cumulative dose, time on amikacin therapy, and
amikacin dose (in milligrams per kilogram, both as daily dose and cumu-
lative dose), area under the concentration-time curve from 0 to 24 h
(AUC0 –24), cumulative AUC, peak concentration, and trough concentra-
tion. Many of these measures are highly correlated, but CART is designed
to break such colinearity. Second, we performed CART analyses focused
solely on the pharmacokinetic and treatment factors identified in the first
step for better identification of threshold values that predicted hearing
loss. Third, we performed CART analyses in which we forced a pick of
peak and trough concentrations as predictors, given the wide use of these
parameters for clinical care. Priors were set to equal, i.e., all categories had
equal probability assignment, with no penalty sets for misclassification.
Gini methods were used for building trees together with 5-fold cross-
validation of each tree, restricting to 3 subjects per node (15). Area
under the receiver operating characteristic curve (AUROC) and parsi-
mony were used to assess and choose trees during pruning.
Analysis using frequentist statistics. Comparisons of proportions
were made using Fisher’s exact  tests, while Kruskal-Wallis or Student’s t
tests were used to compare the medians or means. Estimates of potential
predictors of ototoxicity identified in CART, such as cumulative AUC,
initial patient weight, and the time on amikacin therapy associated with
ototoxicity in 50% of the maximal proportion of patients with ototoxicity
(50% toxic concentration, or TC50) and the 95% confidence intervals
(CI), were calculated by an analysis of probits. All analyses were two sided
with alpha set at 0.05 and performed with STATA software, version 13
(StataCorp LP, College Station, TX).
Design of optimal sampling times for clinical decision making. In
order to identify a sampling strategy that would give clinicians a good
description of the entire AUC0 –24, we applied optimal sampling theory to
the amikacin pharmacokinetic parameters we identified in the MDR-TB
patients. This allows blood draws to be performed at particular informa-
tion-rich time points, after at least 3 half-lives, to allow for identification
of unbiased pharmacokinetic parameter estimates with a minimum num-
ber of samples. We ran this application in the subroutine SAMPLE of
ADAPT 5 and set upper and lower limits of 0 and 24 h, a maximum of 999
iterations, and selected D-optimality criterion.
RESULTS
Our systematic literature search identified three clinical studies
that examined the question of amikacin ototoxicity in patients
(23–25). Two were retrospective studies that did not measure
drug concentrations. Renal dysfunction, old age, and male gender
were identified as risk factors on logistic regression (23, 24). The
third study measured amikacin concentrations in 22 patients, but
only four of the patients had tuberculosis (25). Thus, no prior
studies formally investigated the role of amikacin concentration in
tuberculosis.
Twenty-eight patients in Botswana who had MDR-TB had
amikacin concentration measurements and audiometry assess-
ments. The clinical and demographic characteristics of these pa-
tients are shown in Table 1. The mean age and mean body weight
on initiating therapy did not significantly differ by gender (P 
0.301 and P  0.172, respectively). All HIV-infected patients were
on combination antiretroviral treatments, either nevirapine with
zidovudine-lamivudine or efavirenz with zidovudine-lamivudine
or tenofovir-emtricitabine. Of the 10 patients with prior amin-
oglycoside exposure, 6 had been on streptomycin for category II
treatments and 4 for category IV MDR-TB treatments. Four of 10
patients had prior aminoglycoside exposure, whereas 3/18 pa-
tients without prior exposure developed ototoxicity (P  0.172).
Amikacin pharmacokinetics were best explained by a 2-com-
partment model, with the model predicted versus observed con-
centrations shown in Fig. 1. The pharmacokinetic parameter esti-
mates of amikacin are shown in Table 2. We used the parameter
estimates in each patient to identify the AUC0 –24, to calculate the
cumulative AUC, and to identify the distribution of these param-
eters and the observed drug concentrations, with results shown in
Fig. 2. As expected, cumulative dose (days · milligrams per kilo-
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grams) correlated closely with cumulative AUC (r2  0.87) and
duration of therapy (r2  0.95), given that duration of therapy is a
common variable for the two other parameters. The other con-
centration measures did not closely correlate with each other, in-
cluding peak versus AUC0 –24 (r
2  0.27), peak versus trough (r2 
0.08), trough versus AUC0 –24 (r
2  0.16), peak versus cumulative
AUC (r2  0.31), and trough versus cumulative AUC (r2  0.10).
Hearing loss was encountered in 11/28 (39%) patients based
on subjective reporting but in only 7/28 (25%) confirmed by au-
diograms. The median duration of amikacin therapy to confirmed
hearing loss (range) was 177 (126 to 896) days, showing that the
hearing loss observed in these patients was chronic onset instead
of the reversible form, which tends to be acute onset. Three pa-
tients with confirmed hearing loss did not report any tinnitus, but
out of the 9 patients who reported tinnitus, only 4 (44%) were
confirmed by audiometry (Tables 1 and 3). Table 3 compares the
pharmacokinetic parameters and demographics in patients with
and without hearing loss, based on frequentist statistical infer-
ences. This standard statistical approach, which averages out con-
centrations between the groups, obscures pharmacokinetic
variability effects shown in Fig. 2. No statistically significant dif-
ferences between patients with hearing loss and those without
were observed using this statistical approach.
CART identified deep trees of predictors for confirmed hearing
loss for which the primary node was duration of therapy, which
was followed closely by several of the measures of cumulative drug
exposures, including cumulative AUC, cumulative dose, and cu-
mulative dose divided by weight, followed by AUC0 –24 and patient
weight. Peak and trough were not identified as significant predic-
tors. We next ran a CART model that focused on drug dose factors
and pharmacokinetics, including drug measurements such as
peak and trough. CART analysis identified the primary node as
cumulative days of therapy, while cumulative AUC was ranked
second and improved on the primary node by another 87%, fol-
lowed by AUC0 –24 with a score of 34% and initial weight with a
score of 29%. The model AUROC for the test sets was 0.97. This
was confirmed in cross-validation, performed by the algorithm
randomly splitting the data set into training and test data sets
multiple times; predictive power is the performance of the train-
ing set-derived tree on the test data set. Figure 3 shows the CART
analysis output when drug concentration measures were exam-
ined solely as potential predictors in order to more accurately
identify the concentration cutoff thresholds. Finally, prior to dis-
carding peak and trough, we ran yet another CART model that
was forced to pick the trough and peak as predictors. The AUROC
on the test set was 0.46; thus, it was inferior to the 0.97 in the
model that picked the duration of therapy and cumulative AUC.
Thus, single-snapshot measures of drug exposures such as peak or
trough amikacin concentration were unequivocally poorer pre-
dictors of ototoxicity in MDR-TB patients compared to duration
of therapy, cumulative AUC, and AUC0 –24.
We next examined the relationships between duration of ther-
apy, cumulative AUC, and weight using probit models. Figure 4
shows that the probability of ototoxicity can be reliably estimated
mathematically as a function of each of these 3 parameters. The
relationship between each of these parameters and probability of
ototoxicity was sigmoidal, as described by equations shown in Fig.
4. The amikacin cumulative AUC TC50 was 87,323 (CI, 81,248 to
93,216) days · mg · h/liter, while the TC80 was 120,238 days · mg ·
h/liter. Similarly, Fig. 4C shows that by day 166.7 (CI, 152.8 to
180.6), the probability for ototoxicity starts to increase steeply and
approached near certainty by day 280 (9 months).
Four patients had subjective hearing loss that was not con-
firmed by audiometry: two had cumulative AUCs of 156,423.3
and 144,217.7 days · mg · h/liter. Of the other two, one HIV-
infected patient had a cumulative AUC of 36,466.56 days · mg ·
h/liter but was concurrently on tenofovir, efavirenz, and emtric-
itabine, which have the potential for ototoxicity (26).
Finally, given the role of cumulative AUC identified by CART
and probit analysis, concentrations for clinical decision making
will need to include enough time points to better calculate AUCs
for each patient. The application of optimal sampling theory in
TABLE 2 Population pharmacokinetic parameter estimates in 28 MDR-
TB patientsa
Pharmacokinetic parameter Mean % RSE SD (as %CV)
Total clearance (liter/h) 1.47 245 23.6
Volume of central compartment (liter) 2.10 562 171
Intercompartmental clearance (liter/h) 7.17 614 29
Volume of peripheral compartment 0.25 245 13.6
Absorption constant 2.89 114 4.43
a CV, coefficient of variation; RSE, relative standard error; SD, standard deviation.
TABLE 1 Demographic and clinical characteristics on 28 patients
enrolled in the study
Clinical variable Value (n  28)
No. (%) female 12 (43)
No. (%) HIV infected 12 (43)
No. (%) on antiretroviral therapy 12 (43)
No. (%) with hearing loss 11 (39)
Subjective 11 (39)
Tinnitus 9 (32)
Audiometry confirmed 7 (25)
Mean (SD) age (yr) 44 (18)
Mean (SD) initial wt (kg) 50.57 (10.34)
No. (%) with prior aminoglycoside exposure 10 (36)
Median (range) amikacin dose (mg) 875 (400–1,000)
Median (range) therapy duration (days) 183.5 (28–866)
Median (range) cumulative dose (mg) 94,914 (17,864–601,394)
Observed concentration
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FIG 1 Observed concentrations versus model prediction. A two-compart-
ment model (central compartment or serum versus peripheral compartment)
described the amikacin pharmacokinetics in MDR-TB patients in Botswana
well, with an r2 of 0.997.
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ADAPT identified 0, 15 min, 2.5 h, and 18.7 h as the best times for
blood draw. If the currently used 0.5-h sampling time was fixed,
the model chose 0, 2.7 h, and 18.7 h, which are virtually the same
as those for the nonfixed analysis. Thus, for therapeutic drug
monitoring of amikacin during MDR-TB treatment, the best time
points are 0, 15 min, 2.5 h, and 18.7 h, not peak and trough.
DISCUSSION
We identified amikacin compartmental pharmacokinetic param-
eters in patients on long-term treatment for MDR-TB. The ami-
kacin clearance was relatively uniform with minimum between-
patient variability, consistent with renal clearance in patients with
normal renal function. However, the volume of the central com-
partment had a large between-patient variability, with a 57-fold
range difference from highest to lowest, higher than that seen in
studies of short-term amikacin therapy duration (27, 28). This
means that there will be a wide variability in peak concentrations
even if patients were given the same amikacin dose in Botswana.
The reasons are unclear. We utilized these individual pharmaco-
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FIG 2 Distribution of amikacin concentrations in the 28 patients. (A) Peak concentrations were normally distributed based on the D’Agostino and Pearson omnibus
normality test (P  0.774). The ratio of the lowest to highest peak concentration was 3.49. (B) Trough concentrations were not normally distributed (P  0.001). Fifty
percent of patients had a trough below the limits of detection. (C) The AUCs were normally distributed (P  0.223); the ratio of the lowest to highest AUC was 4.09. (D)
The cumulative AUCs were not normally distributed (P  0.001) and had an even wider range, with a ratio of highest to lowest cumulative AUC of 33.67.
TABLE 3 Comparison of clinical and pharmacokinetic characteristics in patients with or without hearing loss
Variable
Value(s) for patients with:
P value
Confirmed hearing loss
(n  7)
Subjective hearing loss without
confirmation (n  4) No hearing loss (n  17)
Demographics
No. (%) female 5 (71) 0 7 (41) 0.069
No. (%) HIV infected (%) 2 (29) 2 (50) 8 (47) 0.789
Age (yr; range) 52 (28–57) 44.5 (28–70) 40 (29–65) 0.978
Initial wt (kg; range) 47.5 (41.2–57.8) 50.13 (45.0–59.8) 53.1 (42.5–58.5) 0.904
Amikacin doses and concentrations
Dose (mg; range) 750 (750–1,000) 750 (500–1,000) 1000 (750–1,000) 0.875
Cumulative dose (days · mg; range) 140,679 (91,251–182,502) 100,418 (45,626- 174,898) 91,251 (45,625–152,085) 0.344
AUC0–24 (mg · h/liter; range) 548 (486–672) 546 (364–725) 569 (507–680) 0.881
Cumulative AUC (days · mg · h/liter; range) 90,539 (77,254–159,482) 96,833 (33,186–127,452) 96,479 (56,729–151,080) 0.449
Peak (mg/liter; range) 44.92 (31.68–65.59) 44.19 (22.02–59.97) 49.42 (39.00–62.02) 0.662
Trough (mg/liter; range) 0.70 (0–1.23) 0.71 (0–1.87) 0.35 (0–0.76) 0.734
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kinetic factors, in toto with all other clinical factors, with no prior
assumptions of predictors or their distribution (i.e., agnostic), in
machine learning algorithms to identify predictors of ototoxicity.
Standard frequentist statistical inferences, which use measures of
central tendency, failed to identify any associations, as shown in
Table 3. On the other hand, despite the sample size, a pharmaco-
metrics-based approach in tandem with nonparametric CART
identified the main predictors of ototoxicity as duration of ther-
apy and cumulative amikacin AUC. This relationship also was
identified using parametric probit models; thus, it likely will hold
even as sample size increases. Peak and trough concentrations
were poor predictors of ototoxicity and also correlated poorly
with AUC0 –24 and cumulative AUC.
Our results are in accordance with animal model studies by
Beaubien et al., who examined amikacin ototoxicity in albino
guinea pig experiments (29, 30). They found that ototoxicity
best correlated with both plasma cumulative AUC and dura-
tion of therapy and not peak or trough concentrations. The
relationship between plasma cumulative AUC and hearing loss
in the guinea pig experiments was also sigmoidal. They dem-
onstrated that the rate of amikacin entry into perilymph and
endolymph was proportional to the plasma cumulative AUC; it
was this high cumulative amikacin AUC in the organ of Corti
that damaged hair cells (29–31). Thus, our findings using an
agnostic artificial intelligence approach that examined all clin-
ical factors as potential predictors identified factors similar to
those found in the animal experiments. These concordant an-
imal results give a biological basis for, and mechanistic consis-
tency with, our clinical findings.
We identified the cumulative AUC and therapy duration
threshold values that clinicians treating pulmonary tuberculosis
could use for monitoring patients. The decision making depends
on the probability of ototoxicity that clinicians are willing to tol-
erate: a 10% probability occurs with a threshold cumulative AUC
of 87,232, while that of 20% is 120,000 (Fig. 4). This decision
needs to be balanced versus the 75% therapeutic cure rate, which
also could be concentration dependent. While the AUC is the
speed toward target (cumulative AUC), the duration of therapy
constitutes the distance to that target. The inflection point is at
about 6 months of therapy (Fig. 4C), suggesting a limit for the
amikacin therapy duration with regard to ototoxicity. On the
other hand, patients with higher AUCs will have a higher inci-
dence of ototoxicity earlier than the 6 months (higher so-called
speed toward the cliff), so that if concentrations can be measured
the optimal duration of therapy for safety then can be calculated
during the first week of therapy. We identified the best time points
as just prior to dose and 15 min, 2.5 h, and 18.7 h after dose for
blood draws in tuberculosis programs for amikacin therapeutic
drug monitoring.
Our study has several limitations. Amikacin has a long half-life
in cochlear tissue; as a result, hearing loss has been known to occur
long after cessation of therapy. Second, we only measured amika-
cin concentrations, even though MDR-TB patients receive several
other drugs that could contribute to ototoxicity. Third, we did not
have sufficient data on streptomycin exposure prior to receiving
MDR-TB treatment in the study; therefore, we could not examine
the relationship between this aminoglycoside exposure and oto-
toxicity. Fourth, defining ototoxicity is still an imprecise science.
Most conventional audiometers test low frequencies up to 8 kHz,
just enough to be within the regular hearing and speech ranges of
0.3 to 3 kHz. However, amikacin affects higher-frequency hearing
loss, up to 20 kHz, earlier and more frequently than it does the
lower ones (32). Some patients might not be aware that they have
such high-tone deafness. In our study, one of the four patients
with subjective hearing loss could have met that definition. None-
theless, if all four patients were considered probable cases of oto-
toxicity, the computed incidence from this study, 11/28 (39%),
would be within range of other widely reported estimates for ami-
noglycoside toxicities, including amikacin (23–25).
In summary, we identified cumulative AUC and duration-of-
therapy thresholds as predictors of amikacin ototoxicity. Peak and
trough concentrations which are currently used for clinical deci-
sion making were not predictors. We identified cumulative AUC
FIG 3 Optimum classification and regression analysis tree to identify concentration thresholds. The tree identified cumulative AUC thresholds of 54,519 and
91,914 days · mg · h/liter.
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and duration of therapy thresholds predictive of the ototoxicity.
These thresholds can be used for clinical decision making.
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FIG 4 Probability of ototoxicity as a function of three different parameters.
The probability of ototoxicity as a function of cumulative AUC is sigmoidal,
with the TC50 of 87,232 days · mg · h/liter shown in the equation. This value is
very close to the 91,914 days · mg · h/liter identified by CART. The more
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can be tolerated by clinicians and patients. (B) Probability of ototoxicity as a
function of patient weight. Since this is a nonmodifiable patient factor at the
time when a patient presents with MDR-TB, it would not factor much in the
decision making. (C) Probability of ototoxicity as a function of duration of
therapy. The risk increases at the inflection point of 6 months and is a near
certainty at 9 months.
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